Führungskraft von Seres Therapeutics veräußert Aktien in a value of 397 US-Dollar from Investing.com

Teresa L. Young, Executive Vice President and Chief Commercial & Strategy Officer at Seres Therapeutics, Inc. (NASDAQ:MCRB), at kürzlich 735 Stammaktien des Unternehmens veräußert. The transaction took place on 18.11.2024 with a term of 0.541 US Dollars for Action, and an amount of 397 US Dollars was raised.

The purchase price was determined by the deadlines Rule 10b5-1 Handelsplans durchgeführt was decided by March 5, 2023. These plans should mainly be implemented in the form of a savings plan with coverage of Restricted Stock Units. After this transaction, Young stops weiterhin 90.404 Aktien von Seres Therapeutics.

Darüber is young on 15.11.2024 2,656 Aktien by the Übertragung von Restricted Stock Units, was not a direct monetary transaction. These events are among the announced plans that started in February 2024.

In others, Seres Therapeutics’ integrated treatment approaches have been clinically and financially funded for the third quarter of 2024. This is one of the most likely results from the SER-155 Phase Ib clinical trial following from VOWST-Verkaufs and Nestlé Health Science. With a net income of 51 million US dollars in the quarter, most likely due to the payment of oaktree debt and small income tax, the external connections can be abbauen and the business optimizations.

Seres Therapeutics continues with the new Live Biotherapeutic Program and the treatment of SER-155 with various patient groups. You can rely on Unternehmen aktiv nach Partnerschaften zur Förderung seiner Forschungs- und Entwicklungsinitiativen.

I have received a number of message notifications of one of the 77% reduced bacterial infections in patients from the SER-155 Phase Ib Cohort 2 clinical trial. The VOWST-Verkauf and Nestlé Health Science brought the Unternehmen erhebliche Vorabzahlungen ein, the sowohl die Schuldentilgung as a personal abbau a 100 Mitarbeiter ermöglicht. The financial financing of the US economy at a level of 66.8 million US dollars, which would prepare the bet in four quarters of 2025, would take place.

InvestingPro Insights

Während Seres Therapeutics through turbulent times, actively uses InvestingPro data at the financial low age. With a market capitalization of US$117.42 million, the young Abwärtsdruck reflects more broadly on the Aktienkurs. This company said that it is German in the performance of the activity, it is about a turnover of 31.67% and in the third month a turnover of 38.99% is recorded.

These matters are with two important InvestingPro Tips: Zum een ​​hat die Aktie “in der letzten Woche een erheblichen Einbruch erlitten”, was Teil eines breiteren Trends schwacher Performance ist. Zum others “verbrennt das unternehmen rasch bargeld” – a critical problem for biotechnology unternehmen with seres therapies, which are often a capital mixture for Research and Entwicklung benötigen.

The most recent insider publication by Teresa L. Young, which is relatively relative and one of the most successful plans, aims to improve the background of the financing of herausforderungen. The beach is true, the analysts have received a new InvestingPro tip, but it is not the case that the companies can be profitable in that time. That is in the Einklang with the reported bet of -42.39 million US dollars for the letzten zölf Monate.

Before you dive into some of the analysis, InvestingPro offers 10 other therapy tips, which are more detailed in the financial well-being and market position of our other options.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.